Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 10:50
ALNY screens as decent value: peer-relative discount, strong growth and profitability, but leverage, dilution, and earnings volatility pose risks.
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
08.10.2026 10:50
ALNY screens as decent value: peer-relative discount, strong growth and profitability, but leverage, dilution, and earnings volatility pose risks.
3 Great Healthcare Stocks To Own In October 2026
02.10.2026 13:12
Global bond markets have just steadied after a sharp sell off that pushed US borrowing costs to levels last seen in 2002, which keeps reliable cash generation and robust finances firmly in focus. That backdrop puts financially solid healthcare leaders, from drug developers to equipment makers, on many watchlists. This article walks through three stand out stocks from a curated healthcare shortlist that meet those quality filters. The three healthcare stocks highlighted next are only a...
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
29.09.2026 13:00
CAMBRIDGE, Mass., September 29, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earl
Alnylam Needs Stronger Amvuttra Execution To Justify More Upside
26.09.2026 06:06
Alnylam at its current ~$255 valuation leaves limited upside without stronger commercial execution, especially for AMVUTTRA. Learn why ALNY stock is a hold.
RNAi drug specialist ADARx raises $446M IPO
25.09.2026 00:36
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
20.09.2026 01:01
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
18.09.2026 10:42
RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript
17.09.2026 16:08
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control September 17, 2026...
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control - Slideshow
17.09.2026 12:59
2026-09-17. The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14.09.2026 13:11
Alnylam Pharmaceuticals, Inc. (ALNY) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsYvonne...
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
10.09.2026 11:44
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
08.09.2026 11:55
Alnylam Pharmaceuticals, Inc. (ALNY) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 8:45 AM EDTCompany ParticipantsJohn Kennedy - Senior...
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech
03.09.2026 08:04
Alnylam (NASDAQ:ALNY) passes the Affordable Growth screen with strong growth, reasonable valuation, solid profitability, and healthy financials.
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
24.08.2026 08:35
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention
20.08.2026 10:51
Decent Value screen flags Alnylam Pharmaceuticals (ALNY) for strong growth, solid profitability, and reasonable forward valuation.
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
11.08.2026 09:30
U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.
Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
06.08.2026 12:30
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
04.08.2026 01:54
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.
Alnylam (ALNY) Q2 2026 Earnings Call Transcript
04.08.2026 01:54
TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.